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Abstract
Background: We describe trends in participation by investigators from low- and middle-income countries (LMCs) in
publications describing oncology randomized control trials (RCTs) over a decade.
Methods: We used Medline to identify RCTs published in English from 1998 to 2008 evaluating treatment in lung,
breast, colorectal, stomach and liver cancers. Data on author affiliations, authorship roles, trial characteristics, funding
and interventions were extracted from each article. Countries were stratified as low-, middle- or high-income using
World Bank data. Interventions were categorized as requiring basic, limited, enhanced or maximal resources as per the
Breast Health Global Initiative classification. Logistic regression was used to identify factors associated with authorship
by investigators from LMCs.
Results: 454 publications were identified. Proportion of articles with at least one LMC author increased over time from
20% in 1998 to 29% in 2008 (p=0.01), but almost all LMC authors were from middle-income countries. Proportion of
articles with at least one LMC author was higher among articles that explicitly reported recruitment in at least one LMC
vs those that did not (76% vs 13%). Among 87 articles (19%) that involved authors from LMCs, 17% had LMC authors as
first or corresponding authors, and 67% evaluated interventions requiring enhanced or maximal resources. Factors
associated with LMC authorship included industry funding (OR=3.54, p=0.0001), placebo comparator arm (OR=2.57,
p=0.02) and palliative intent treatment (OR=4.00, p=0.0003).
Conclusion: An increasing number of publications describing oncology RCTs involve authors from LMC countries but
primarily in non-leadership roles in industry-funded trials.
Keywords: Randomized controlled trials, Publications, Cancer, Low and middle income countries, Authorship,
Sponsorship
Introduction
Low- and middle-income countries (LMCs) dispropor-
tionately bear the rising global cancer burden [1,2]. Clin-
ical research needs to address this high cancer burden in
resource-limited settings, but only 10% of world’s ex-
penditure on health research has focused on issues in
lower resource settings [1,3,4]. Simultaneously, clinical
trials are becoming increasingly globalized. From 1995
to 2005, trial participation in sites outside of the United
States more than doubled, including LMCs [5,6]. A re-
cent study found that 78% of clinical trials evaluating
cancer therapies published between 2007 and 2011 were
conducted in developed countries, while 22% of trials
were conducted in developing countries [7]. However,
few studies have quantitatively addressed the role of
LMC investigators in global clinical trials or ethical is-
sues associated with their participation [8].
To capture the level of involvement by investigators
from different countries in randomized oncology trials,
we systematically reviewed a cohort of published trials
and describe trends in participation in these publications
by LMCs investigators. Trial involvement includes tasks
such as enrolling patients (participation) as well as more
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results (authorship). Our primary focus was on author-
ship trends but we also describe trends in other tasks
where the information was available. We focused on on-
cology randomized control trials (RCTs) over a decade
(1998–2008), specifically documenting the role of LMC
investigators in clinical trials as reflected in the publica-
tion and the applicability of these trials to local resource
settings when LMCs participated. We hypothesized that
LMC authorship and participation in publications de-
scribing oncology RCTs increased over time, but that
few LMC authors had leadership roles and few trial in-
terventions were relevant to lower resource settings even
when LMC investigators were involved.
Methods
Identification of studies
All phase III clinical trials from January 1, 1998 to
December 31, 2008 evaluating treatment in five cancer
cancers (lung, breast, colorectal, stomach, liver) were
systematically identified from MEDLINE. We selected
these cancers based on GLOBOCAN 2002 and American
Cancer Society statistics which showed these cancers have
the highest global mortality rates. Details of the search are
listed in the Appendix. Articles retrieved from MEDLINE
were then manually screened for inclusion in the study.
Inclusion criteria were: 1) pertaining to one of 5 cancer
sites (lung, breast, colorectal, liver or stomach), 2)
published in English language, 3) evaluating a treat-
ment intervention (chemotherapy, radiation therapy,
surgery, palliative care, hormones or monoclonal anti-
bodies/targeted agents), and 4) absence of exclusion
criteria. Exclusion criteria were: 1) prevention, screen-
ing or diagnostic procedure trials, 2) articles presenting
follow-up or updated data from previously published
trials, or 3) sub-studies.
Data abstraction
From each article, information was extracted directly
into a pre-designed electronic database, which under-
went pilot testing to ensure face validity and inter-
observer reliability. The following data were included: 1)
year of publication, 2) country affiliations of first, corre-
sponding and middle authors, 3) country affiliations of
participating centers and additional investigators (where
available), 4) trial characteristics, 5) types of treatment,
6) documentation of ethics, informed consent and fund-
ing sources, and 7) whether relevance of study to LMCs
was discussed. Based on Gross National Income data
available from World Bank statistics (2009), countries
were stratified into high ($11,456 or more per capita),
middle ($936-$11,455) and low ($935 or less) income
groups. Corresponding author was defined as the pri-
mary contact author for the publication, while senior
author was defined as the last author on the author list.
First, corresponding or senior authorship positions were
deemed as leadership roles. Participating centers were
defined as institutions that were listed in the publication
as having enrolled study participants. Interventions were
divided into basic, limited, enhanced and maximal cat-
egories based on estimated cost and resources required
for implementation as established previously for breast
cancer and by one of the authors (MKK) for the other
cancer sites applying general guiding principles set out
by the Breast Health Global Initiative [9]. Briefly, we
considered basic resources to be core healthcare services
(e.g. modified radical mastectomy); limited resources
were key services that required limited finances and
infrastructure (e.g. cyclophosphamide, methotrexate, 5-
fluorouracil); enhanced resources were optional services
that increased the number and quality of therapies (e.g.
taxanes); and maximal resources were services that had
lower priority in lower resource settings due to high cost
or impracticality (e.g. growth factors) [9]. Ethics were re-
ported as documented if the publication explicitly stated
that ethics approval was obtained for the study.
Statistical analysis
Summary statistics were used to present the data. We
examined associations between whether studies had any
authors from a low or middle income country (yes or
no) and the following variables: year of publication,
cancer site, funding type, multi- versus single-centre par-
ticipation, use of placebo, type of treatment, treatment
aim, type of randomized trial, ethics documentation, and
whether the study mentioned informed consent. Adjusted
analyses were performed using logistic regression, entering
all variables into the model except for whether the study
mentioned informed consent, due to small cell counts. No
evidence of multi-collinearity was found (all variables had
tolerances>0.4). Assessment of the model’s calibration with
the Hosmer-Lemeshow test (p-value =0.67) and discrimin-
ation (C-statistic =0.76) did not show lack of fit. Graphics
were created in R v 2.13.1 (R Development Core Team,
Vienna, Austria) and statistical analyses were conducted
using SAS version 9.0 (SAS Institute Inc, Cary, NC).
Results
Search results
The MEDLINE search identified 876 publications de-
scribing RCTs in lung, breast, colorectal, stomach and
liver cancers, of which 454 publications met inclusion
criteria. Table 1 summarizes characteristics of these pub-
lished trials: trials in lung and breast cancer made up the
largest proportion of the cohort. Most trials used simple
two-arm designs and focused on systemic cancer treat-
ment such as chemotherapy. More than half of the trials
evaluated treatment interventions given with palliative
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Approximately 10% used a placebo in the comparator
arm. About 42% of trials identified industry as a funding
source either exclusively or in combination with other
funding sources.
Figure 1 summarizes temporal trends in the number
of publications, stratified by the number of authors or
participating centers from LMCs. The number of RCTs
published per year increased from 10 in 1998 to 86 in
2008. LMC participation also increased over time from
20% in 1998 to 29% in 2008 (p=0.01), but most of this
increased participation was in non-leadership roles.
Authors and participating centers
Figure 2 illustrates the level of participation of each
country in RCTs for our study cohort and the number of
authors from each country in leadership positions. The
median number of authors per publication in our RCT
cohort was 12 (range 1–35). Of 454 first authors, 276
could be linked to an academic affiliation or clinical
institution, and 440 could be linked to a country. First
authors were most commonly from the United States
(n= 108), Italy (n= 52) or United Kingdom (n= 34).
Corresponding authors were most commonly from the
United States (n= 113), Italy (n =53) or Germany (n=
35). Senior authors were most commonly from the
United States (n= 63), Italy (n= 43) or Japan (n= 26).
There were no first or corresponding authors from a
low-income country, and only two first authors and
two corresponding authors from a lower-middle in-
come country (India).
More publications included middle authors from LMCs.
Two publications included middle authors from low in-
come countries: Cambodia (n=1) and Cameroon (n=1).
Multiple publications included middle authors from low-
middle income countries: India (n=7), China (n=4),
Egypt (n=4), Pakistan (n=4), Ukraine (n=3), Philippines
(n=1), Thailand (n=1) and Tunisia (n=1).
In addition, we analyzed authorship trends after strati-
fying by whether the study was conducted in an LMC,
high income country or both. The exact number of par-
ticipating centers was documented in 271 of 454 (60%)
publications. The median number of participating cen-
tres was 29 (range 1–478). 257 publications (57%) docu-
mented the countries involved, so this sub-analysis was
limited to this cohort (summarized in Table 2). Centers
were most commonly in the United States (n =61), Italy
(n =58) and Germany (n = 49). Additional investigators
who were not authors were acknowledged in 160 publi-
cations, and their country affiliations were documented
in 154 publications. Ten publications acknowledged
participation from LMC centers, but did not have any
authors from LMCs. Two studies were conducted exclu-
sively in LMCs; both had at least one author from an
LMC, and at least one author from an LMC in a lead-
ership role. Forty studies (9%) were conducted in both
LMCs and high income countries; in these studies 30
(75%) had at least one author from an LMC, and 7%
had at least one author from an LMC in a leadership
role. Two hundred and fifteen studies (47%) occurred
in high income countries, with 3 (1%) of these studies
including at least one author from an LMC in a non-
leadership role.
Table 1 Characteristics of the cohort of oncology RCTs
included in the analysis
Variable Number of papers
(N=454)
Percentage
Cancer site
Lung 177 39.0
Breast 165 36.3
Colorectal 82 18.1
Stomach 29 6.4
Liver 7 1.5
Trial design
Simple two-arm 393 86.6
Multiple arms 48 10.6
Factorial 13 2.9
Use of placebo
Yes 41 9.0
No 413 91.0
Treatment aim
Adjuvant/Curative 140 30.8
Metastatic/Palliative 241 53.1
Both 43 9.5
Supportive measures 30 6.6
Treatment type
Chemotherapy 367 80.8
Surgery 15 3.3
Hormones 40 8.8
Best supportive care 6 1.3
Radiation 66 14.5
Monoclonal antibodies/targeted
agents
63 13.9
First line treatment
Yes 309 68.1
No 145 31.9
Funding source
Industry 154 33.9
Mixed 39 8.6
Not for profit 107 23.6
Not specified 154 33.9
Wong et al. Globalization and Health 2014, 10:83 Page 3 of 9
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Figure 2 Map of countries with authors or participating centers in oncology trial publications. Each country is coded with a color
indicating the number of oncology trial publications (light to dark) with a participating center or an author from that country. Each country also
has a black symbol (dot) indicating the number of publications with authors from that country in leadership roles.
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conducted in a low and/or high income country, we also
analyzed collaboration patterns between low and high
income countries for multi-institutional studies (N=263).
Results are presented in Table 3. There was insufficient
data for this analysis in 62 studies. Of the remaining 201
studies, one study was conducted in an LMC setting only,
with authors from more than one LMC. Thirty four
studies were conducted in LMCs and high income
countries; 26 of these studies included at least one au-
thor from an LMC in addition to authors from high
income countries. One hundred and sixty six studies
were conducted in high income countries only with
the majority of the trials (131, 79%) having authors
from only one high income country.
Funding and ethics
Funding sources are summarized in Table 1. Involvement
of LMC authors or participating centres stratified by fund-
ing source is illustrated in Figure 3. Notably, the propor-
tion of studies involving LMC investigators or centres was
highest among purely industry funded trials: 40% of
industry-only funded trials had LMC participation, while
15% of trials funded by not-for-profit sources reported
LMC participation.
Ethics approval was mentioned in 364 of 454 arti-
cles. Informed consent was mentioned in 428 of 454
articles. Only two articles stated that all participants
had to speak English fluently. Only 1 article docu-
mented that consent forms were translated into a
language other than English.
Relevance to lower resource settings
Figure 3 also shows the number of publications that re-
ported RCTs testing interventions at four resource levels
(basic to maximal), broken down by whether LMC
authors or participating centers were involved. Almost
no studies focused on interventions compatible with
basic resources, with majority of trials evaluating inter-
ventions that required at least enhanced resources for
delivery. Among trials that included LMC investigators,
67% evaluated interventions requiring enhanced or
maximal resources. Only 3 studies explicitly mentioned
the relevance of treatment under evaluation to lower
resource settings in either the discussion or conclusion:
these studies briefly mentioned treatment costs in con-
sidering treatment, or geographic characteristics that
limit medical care.
Variables associated with LMC authorship
Results of the univariable and multivariable logistic
regression models are summarized in Table 4. In
univariable analysis, more recent publications (versus
earlier publications), industry sponsorship (versus not-for-
profit sponsorship), placebo-controlled trials (versus trials
without the use of placebo) and trials performed in the
metastatic setting (versus trials in the adjuvant setting)
were more likely to have at least one author from an
LMC. These factors remained significant in multivariable
analysis. More recently published trials, placebo-controlled
trials, industry funded trials and trials in the metastatic set-
ting were more likely to have an LMC author.
Discussion
Through this systematic review, we found that the abso-
lute number of publications describing oncology RCTs
and the proportion of these publications that involved
LMC investigators as authors increased over time. Most
of the increased LMC authorship involved investigators
from middle- rather than low-income countries and usu-
ally in non-leadership roles, ie. as middle authors. There
were several publications that listed participating sites in
LMCs but did not include investigators from those sites
as authors. Since not all the publications listed all par-
ticipating sites, while the absolute number of publica-
tions that included LMC authors has increased over
time the proportion of studies that recruit in LMCs and
include at least one LMC author may not be changing
and may even be actually proportionally decreasing over
time. A recent study found that, despite participation in
global clinical trials, researchers from lower resource set-
tings had proportionally lower rates of authorship per
patient enrollment, compared to researchers from higher
resource settings [10]. Our study differs from this previ-
ous study by focusing specifically on publications in the
area of oncology, and addressing additional issues such
as relevance of interventions to LMC settings.
Table 2 Authorship trends by location of study (n= 454)
Where was the study conducted Number of studies (overall) Number of studies with at least one
author from LMIC (any role)
Number of studies with at least one
author from LMIC in a leadership role
Not explicitly reported 197 (43%) 52 (26%) 10 (19%)
LMIC only 2 (<1%) 2 (100%) 2 (100%)
HIC and LMIC 40 (9%) 30 (75%) 2 (7%)
HIC only 215 (47%) 3 (1%) 0 (0%)
Total 454 87 (19%) 14 (3%)
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RCTs were more likely to have authors from LMCs. This
may be related to the spatial scope of the trial as indus-
try funded trials are often larger and multinational thus
there may be more opportunity for LMC investigators to
participate in the trial. Unfortunately, we were unable to
optimally control for spatial scope of the trial as infor-
mation on participating countries was not available for
approximately 40% of the manuscripts. Nevertheless,
participation of LMC investigators in industry funded
cancer trials can theoretically be mutually beneficial:
LMC research centers may reap financial benefits from
participating in industry trials, while the pharmaceutical
industry may reduce costs in multinational trials by
conducting them in LMCs [6,11]. However, ethical
concerns have been raised. LMCs centers traditionally
have less regulation and transparency in the conduct
of research [6,12]. Compared to an average study par-
ticipant from a higher resource setting, the average
LMC study participant more likely perceives financial
compensation for trial participation as substantial, or
lacks understanding about the concept of clinical trials
[6]. The LMC investigators may also be more vulner-
able in industry-funded trials: a recent study showed
that the discrepancies in authorship between lower
and higher resource settings in global clinical trials
were exacerbated when the trials were industry-
funded [10].
Approximately two thirds of the publications in our
cohort that included investigators from LMCs evaluated
interventions that required at least enhanced resources
for their delivery. This concerning finding resonates with
the existing literature on the gap between research ef-
forts and LMC needs. Although LMCs’ involvement in
Table 3 Collaboration patterns in multi-institutional studies by location of study (n =263)
Where was the study conducted Number of studies (overall) Number of studies conducted
in one country
Number of studies conducted
in multiple countries
Missing 62 NA NA
LMIC only 10 0
All authors from one LMIC 0 (0%) NA NA
Authors from >1 LMIC 1 (100%) NA NA
HIC and LMIC 34 0 34
One HIC and One LMIC author 0 (0%) NA 0 (0%)
Authors from >1 HIC and >1 LMIC 26 (76%) NA 26 (76%)
HIC only 166 125 41
All authors from one HIC 131 (79%) 119 (95%) 12 (29%)
Authors from >1 HIC 35 (21%) 6 (5%) 29 (71%)
Total 263 126 75
NA= not applicable.
Figure 3 Funding sources for oncology trial publications. Graphs show the number of publications with A) resource levels required for trial
interventions, B) types of funding source, C) documentation of ethics or regulatory board approval, stratified by the number of authors or
participating centers from low- and middle-income countries (LMCs).
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terventions [5], such interventions may not be feasible
or even affordable in low resource health care systems in
the real-world setting [6,11]. Furthermore, most cancer
drug development efforts do not focus on tumor types
most relevant to LMCs: in a review of phase II and III
cancer drug trials, treatments for cancers of the breast,
lung, prostate and colorectal were most frequently stud-
ied [13]. In higher income countries, there was a correl-
ation between the incidence, prevalence and mortality of
a type of cancer to the number of trials for that specific
cancer [13]. In LMCs, only prevalence correlated, sug-
gesting that trials lacked emphasis on the actual cancers
carrying higher mortality in LMCs [13]. Similar
disconnect between burden of disease and trials con-
ducted in lower resource settings has been found in
other medical conditions [14-16]. However, there are
likely also inherent benefits for LMC centers that par-
ticipate in clinical trials. These include gaining access to
newer therapies, other healthcare provisions or im-
proved quality of care during trials [5,11,17], improving
infrastructure including equipment or human capital
[17], improving global information exchange [5], aca-
demic achievement or scientific progress [11].
Global taskforces have discussed potential solutions
for the high cancer burden in the lowest resource set-
tings. The World Health Organization has developed
global strategies and preventative measures [18]. A
Table 4 Factors associated with LMC authorship in oncology RCTs
Univariate logistic regression Multivariable logistic regression
Variable OR (95% CI) p-value OR (95% CI) p-value
Year
For every 1-year increase 1.11 (1.02 – 1.20) 0.01 1.12 (1.02 – 1.24) 0.02
Site
Lung 1.00 Referent 1.00 Referent
Breast 1.38 (0.82 – 2.33) 0.22 1.34 (0.70 – 2.56) 0.38
Liver/colorectal/stomach 0.66 (0.34 – 1.27) 0.21 0.52 (0.24 – 1.10) 0.09
Funding
Not for profit/Mixed 1.00 Referent 1.00 Referent
Industry 3.63 (2.00 – 6.58) <.0001 3.54 (1.85 – 6.78) 0.0001
Not specified 0.88 (0.44 – 1.79) 0.73 0.95 (0.45 - 2.03) 0.90
Multi-center
No 1.00 Referent 1.00 Referent
Yes 1.24 (0.77 – 2.00) 0.38 0.91 (0.52 – 1.58) 0.74
Placebo-controlled
No 1.00 Referent 1.00 Referent
Yes 3.08 (1.57 – 6.07) 0.001 2.57 (1.19 – 5.54) 0.02
Treatment type
Basic/Limited 1.00 Referent 1.00 Referent
Enhanced/Maximal 1.11 (0.68 – 1.82) 0.68 0.61 (0.32 – 1.16) 0.13
Treatment aim
Adjuvant 1.00 Referent 1.00 Referent
Both 3.67 (1.48 – 9.06) 0.005 5.12 (1.81 – 14.48) 0.002
Metastatic 3.38 (1.75 – 6.55) 0.0003 4.00 (1.90 – 8.43) 0.0003
Supportive measures 2.67 (0.91 – 7.79) 0.07 1.21 (0.35 – 4.17) 0.76
Design
Factorial/multiple arms 1.00 Referent 1.00 Referent
Simple 2 arm 0.96 (0.49 – 1.90) 0.91 0.73 (0.34 – 1.58) 0.43
Ethics
Not documented 1.00 Referent 1.00 Referent
Documented 1.36 (0.73 – 2.54) 0.33 0.76 (0.37 – 1.56) 0.45
Outcome variable is having at least one LMC author.
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zations have addressed breast cancer in LMCs [19]. For
example, the 2007 Breast Health Global Initiative has
developed guidelines for radiation therapy [20], path-
ology [21], treatment resource allocation [22], diagnosis
resource allocation [23] and early detection resource
allocation [24] in breast cancer. The 2010 Breast Health
Global Initiative summit analyzed challenges in breast
cancer management in LMCs [25]. The U.S. Centers
for Disease Control and Prevention, American Cancer
Society and National Cancer Institute are leading
other initiatives [19].
How can we improve cancer treatment and outcomes
in LMCs? Some authors have noted that improvement
in breast cancer survival in the United States occurred
before introduction of technological advances, raising
the possibility that cancer survival in LMCs may be im-
proved by focusing on increased awareness and early de-
tection of cancers and by optimizing primary care and
referral systems [26]. Tele-oncology may also improve
cancer survival in LMCs [27]. A focus on primary pre-
vention and screening, early diagnosis, low cost therapy
and establishment of regional initiatives may improve
care in LMCs [28,29]. Finally, cancer treatment and out-
comes are inextricably linked to research, and while im-
proving access to existing treatments is important, we
feel that investing in research that is relevant to LMCs
will be key to ensure appropriate care relevant to local
settings.
Our review has a number of limitations. First of all,
given the lag between study design and publication, our
review reflected trials that were predominantly designed
in the 1990s. A review of trial registries – ideally mul-
tiple registries to ensure a comprehensive and inter-
national approach – could be helpful to provide a more
current overview of LMC involvement in oncology trials.
We also did not collect information on when studies
were conducted, as studies may have been conducted
several years prior to publication. Nevertheless, our re-
view provides a baseline assessment for future compari-
sons and identifies a number of concerning trends to
monitor. Secondly, a number of publications did not
provide full listings of participating countries. Underre-
porting of participating countries probably leads to an
underestimation of LMC participation more so than
participation from higher resource settings, as higher re-
source settings were more likely to have been also listed
in authorship affiliations. Acknowledgement of LMCs
must be more consistent in published manuscripts.
Lastly, we have limited our search to English language
articles and there is the possibility that LMC relevant tri-
als may have been published in local journals in other
languages. We would encourage future studies to look at
studies published in other languages.
Conclusions
An increasing number of articles describing oncology
RCTs involved LMC authors but primarily in non-
leadership roles. These publications were commonly
industry-funded and often reported interventions that
required at least enhanced resources for implementation.
To minimize concerns of exploitation and expedite glo-
bal research collaborations, it is crucial that trial inter-
ventions are locally feasible and investigators receive
appropriate authorship credits.
Appendix
Search strategy
 A MEDLINE search was conducted (OVID
MEDLINE 1996-June 2009) to identify all published
Phase III clinical trials within a 10 year time frame
(1998–2008) for the 5 tumour types.
 The search was limited to the English language
and humans for the publication years between
1998–2008.
 The search was then limited to include phase III
trials only.
 The results of the search were manually reviewed
to identify treatment trials.
1. Lung Neoplasms/(56805)
2. limit 1 to (english language and humans and
yr ="1998 - 2008") (38278)
3. limit 2 to clinical trial, phase iii (297)
4. Breast Neoplasms/(90306)
5. limit 4 to (english language and humans and
yr ="1998 - 2008") (70178)
6. limit 5 to clinical trial, phase iii (345)
7. Stomach Neoplasms/(23934)
8. limit 7 to (english language and humans and
yr ="1998 - 2008") (15767)
9. limit 8 to clinical trial, phase iii (37)
10. Colorectal Neoplasms/(28766)
11. limit 10 to (english language and humans and
yr ="1998 - 2008") (21816)
12. limit 11 to clinical trial, phase iii (118)
13. Liver Neoplasms/(39339)
14. limit 13 to (english language and humans and
yr ="1998 - 2008") (26242)
15. limit 14 to clinical trial, phase iii (59)
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